AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. EWTX
  4. [Form 4] Edgewise Therapeutics, Inc. Insider Trading Activity

[Form 4] Edgewise Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Edgewise Therapeutics Director Arlene Morris received a stock option grant on June 16, 2025, representing a significant insider transaction. The key details of this Form 4 filing include:

  • Granted 30,000 stock options to purchase common stock
  • Exercise price set at $14.68 per share
  • Options will vest fully on the earlier of June 16, 2026 or the day before the 2026 annual stockholder meeting
  • Options expire on June 16, 2035

This grant appears to be part of the company's director compensation program. The one-year cliff vesting schedule aligns with typical board member equity compensation structures. The filing was completed by Attorney-in-Fact John R. Moore on June 18, 2025.

Arlene Morris, Direttrice di Edgewise Therapeutics, ha ricevuto una concessione di stock option il 16 giugno 2025, rappresentando una significativa transazione interna. I dettagli principali di questo modulo 4 includono:

  • Concessione di 30.000 stock option per l'acquisto di azioni ordinarie
  • Prezzo di esercizio fissato a 14,68 $ per azione
  • Le opzioni matureranno completamente entro la prima tra il 16 giugno 2026 o il giorno precedente l'assemblea annuale degli azionisti del 2026
  • Le opzioni scadranno il 16 giugno 2035

Questa concessione sembra far parte del programma di compensazione per i direttori della societ脿. Il piano di maturazione a un anno 猫 in linea con le strutture tipiche di compensazione azionaria per i membri del consiglio. La presentazione 猫 stata completata dall'Avvocato John R. Moore il 18 giugno 2025.

Arlene Morris, Directora de Edgewise Therapeutics, recibi贸 una concesi贸n de opciones sobre acciones el 16 de junio de 2025, representando una transacci贸n interna significativa. Los detalles clave de este formulario 4 incluyen:

  • Concesi贸n de 30,000 opciones sobre acciones para comprar acciones ordinarias
  • Precio de ejercicio establecido en $14.68 por acci贸n
  • Las opciones se consolidar谩n completamente en la fecha que ocurra primero entre el 16 de junio de 2026 o el d铆a antes de la junta anual de accionistas de 2026
  • Las opciones expiran el 16 de junio de 2035

Esta concesi贸n parece ser parte del programa de compensaci贸n para directores de la empresa. El calendario de consolidaci贸n con un per铆odo de un a帽o es coherente con las estructuras t铆picas de compensaci贸n de capital para miembros del consejo. La presentaci贸n fue completada por el apoderado John R. Moore el 18 de junio de 2025.

Edgewise Therapeutics 鞚挫偓 Arlene Morris電� 2025雲� 6鞗� 16鞚检棎 欤检嫕毵れ垬靹犿儩甓岇潉 攵�鞐皼鞎� 欷戩殧頃� 雮措秬鞛� 瓯半灅毳� 旮半頄堨姷雼堧嫟. 鞚� Form 4 鞝滌稖靹滌潣 欤检殧 雮挫毄鞚� 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 30,000欤�鞚� 氤错喌欤� 毵れ垬靹犿儩甓� 攵�鞐�
  • 頄夓偓臧�瓴╈潃 欤茧嫻 14.68雼煬搿� 靹れ爼
  • 靹犿儩甓岇潃 2026雲� 6鞗� 16鞚� 霕愲姅 2026雲� 鞐半 欤检＜齑濏殞 鞝勲偁 欷� 牍犽ジ 雮犾鞐� 鞝勳暋 旆摑
  • 靹犿儩甓� 毵岆鞚检潃 2035雲� 6鞗� 16鞚�

鞚措矆 攵�鞐姅 須岇偓 鞚挫偓 氤挫儊 頂勲攴鸽灗鞚� 鞚茧秬搿� 氤挫瀰雼堧嫟. 1雲� 韥措Μ頂� 氩犾姢韺� 鞚检爼鞚� 鞚挫偓須� 甑劚鞗愳潣 鞚茧皹鞝侅澑 欤检嫕 氤挫儊 甑“鞕� 鞚检箻頃╇媹雼�. 鞚� 鞝滌稖靹滊姅 氩曤雽�毽澑 John R. Moore臧� 2025雲� 6鞗� 18鞚检棎 鞕勲頄堨姷雼堧嫟.

Arlene Morris, directrice de Edgewise Therapeutics, a re莽u une attribution d'options d'achat d'actions le 16 juin 2025, repr茅sentant une transaction d'initi茅 importante. Les principaux d茅tails de ce d茅p么t du formulaire 4 sont :

  • Attribution de 30 000 options d'achat pour acqu茅rir des actions ordinaires
  • Prix d'exercice fix茅 脿 14,68 $ par action
  • Les options deviendront enti猫rement acquises 脿 la date la plus proche entre le 16 juin 2026 ou la veille de l'assembl茅e annuelle des actionnaires de 2026
  • Les options expirent le 16 juin 2035

Cette attribution semble faire partie du programme de r茅mun茅ration des administrateurs de la soci茅t茅. Le calendrier d'acquisition avec une p茅riode d'un an correspond aux structures habituelles de r茅mun茅ration en actions des membres du conseil. Le d茅p么t a 茅t茅 effectu茅 par le mandataire John R. Moore le 18 juin 2025.

Arlene Morris, Direktorin von Edgewise Therapeutics, erhielt am 16. Juni 2025 eine Gew盲hrung von Aktienoptionen, was eine bedeutende Insider-Transaktion darstellt. Die wichtigsten Details dieser Form 4 Einreichung sind:

  • Gew盲hrung von 30.000 Aktienoptionen zum Kauf von Stammaktien
  • Aus眉bungspreis wurde auf 14,68 $ pro Aktie festgesetzt
  • Die Optionen werden vollst盲ndig unverfallbar am fr眉heren der beiden Termine: 16. Juni 2026 oder dem Tag vor der j盲hrlichen Aktion盲rsversammlung 2026
  • Die Optionen verfallen am 16. Juni 2035

Diese Gew盲hrung scheint Teil des Verg眉tungsprogramms f眉r Direktoren des Unternehmens zu sein. Der einj盲hrige Cliff-Vesting-Zeitplan entspricht typischen Aktienverg眉tungsstrukturen f眉r Vorstandsmitglieder. Die Einreichung wurde am 18. Juni 2025 vom Bevollm盲chtigten John R. Moore abgeschlossen.

Positive
  • None.
Negative
  • None.

Arlene Morris, Direttrice di Edgewise Therapeutics, ha ricevuto una concessione di stock option il 16 giugno 2025, rappresentando una significativa transazione interna. I dettagli principali di questo modulo 4 includono:

  • Concessione di 30.000 stock option per l'acquisto di azioni ordinarie
  • Prezzo di esercizio fissato a 14,68 $ per azione
  • Le opzioni matureranno completamente entro la prima tra il 16 giugno 2026 o il giorno precedente l'assemblea annuale degli azionisti del 2026
  • Le opzioni scadranno il 16 giugno 2035

Questa concessione sembra far parte del programma di compensazione per i direttori della societ脿. Il piano di maturazione a un anno 猫 in linea con le strutture tipiche di compensazione azionaria per i membri del consiglio. La presentazione 猫 stata completata dall'Avvocato John R. Moore il 18 giugno 2025.

Arlene Morris, Directora de Edgewise Therapeutics, recibi贸 una concesi贸n de opciones sobre acciones el 16 de junio de 2025, representando una transacci贸n interna significativa. Los detalles clave de este formulario 4 incluyen:

  • Concesi贸n de 30,000 opciones sobre acciones para comprar acciones ordinarias
  • Precio de ejercicio establecido en $14.68 por acci贸n
  • Las opciones se consolidar谩n completamente en la fecha que ocurra primero entre el 16 de junio de 2026 o el d铆a antes de la junta anual de accionistas de 2026
  • Las opciones expiran el 16 de junio de 2035

Esta concesi贸n parece ser parte del programa de compensaci贸n para directores de la empresa. El calendario de consolidaci贸n con un per铆odo de un a帽o es coherente con las estructuras t铆picas de compensaci贸n de capital para miembros del consejo. La presentaci贸n fue completada por el apoderado John R. Moore el 18 de junio de 2025.

Edgewise Therapeutics 鞚挫偓 Arlene Morris電� 2025雲� 6鞗� 16鞚检棎 欤检嫕毵れ垬靹犿儩甓岇潉 攵�鞐皼鞎� 欷戩殧頃� 雮措秬鞛� 瓯半灅毳� 旮半頄堨姷雼堧嫟. 鞚� Form 4 鞝滌稖靹滌潣 欤检殧 雮挫毄鞚� 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 30,000欤�鞚� 氤错喌欤� 毵れ垬靹犿儩甓� 攵�鞐�
  • 頄夓偓臧�瓴╈潃 欤茧嫻 14.68雼煬搿� 靹れ爼
  • 靹犿儩甓岇潃 2026雲� 6鞗� 16鞚� 霕愲姅 2026雲� 鞐半 欤检＜齑濏殞 鞝勲偁 欷� 牍犽ジ 雮犾鞐� 鞝勳暋 旆摑
  • 靹犿儩甓� 毵岆鞚检潃 2035雲� 6鞗� 16鞚�

鞚措矆 攵�鞐姅 須岇偓 鞚挫偓 氤挫儊 頂勲攴鸽灗鞚� 鞚茧秬搿� 氤挫瀰雼堧嫟. 1雲� 韥措Μ頂� 氩犾姢韺� 鞚检爼鞚� 鞚挫偓須� 甑劚鞗愳潣 鞚茧皹鞝侅澑 欤检嫕 氤挫儊 甑“鞕� 鞚检箻頃╇媹雼�. 鞚� 鞝滌稖靹滊姅 氩曤雽�毽澑 John R. Moore臧� 2025雲� 6鞗� 18鞚检棎 鞕勲頄堨姷雼堧嫟.

Arlene Morris, directrice de Edgewise Therapeutics, a re莽u une attribution d'options d'achat d'actions le 16 juin 2025, repr茅sentant une transaction d'initi茅 importante. Les principaux d茅tails de ce d茅p么t du formulaire 4 sont :

  • Attribution de 30 000 options d'achat pour acqu茅rir des actions ordinaires
  • Prix d'exercice fix茅 脿 14,68 $ par action
  • Les options deviendront enti猫rement acquises 脿 la date la plus proche entre le 16 juin 2026 ou la veille de l'assembl茅e annuelle des actionnaires de 2026
  • Les options expirent le 16 juin 2035

Cette attribution semble faire partie du programme de r茅mun茅ration des administrateurs de la soci茅t茅. Le calendrier d'acquisition avec une p茅riode d'un an correspond aux structures habituelles de r茅mun茅ration en actions des membres du conseil. Le d茅p么t a 茅t茅 effectu茅 par le mandataire John R. Moore le 18 juin 2025.

Arlene Morris, Direktorin von Edgewise Therapeutics, erhielt am 16. Juni 2025 eine Gew盲hrung von Aktienoptionen, was eine bedeutende Insider-Transaktion darstellt. Die wichtigsten Details dieser Form 4 Einreichung sind:

  • Gew盲hrung von 30.000 Aktienoptionen zum Kauf von Stammaktien
  • Aus眉bungspreis wurde auf 14,68 $ pro Aktie festgesetzt
  • Die Optionen werden vollst盲ndig unverfallbar am fr眉heren der beiden Termine: 16. Juni 2026 oder dem Tag vor der j盲hrlichen Aktion盲rsversammlung 2026
  • Die Optionen verfallen am 16. Juni 2035

Diese Gew盲hrung scheint Teil des Verg眉tungsprogramms f眉r Direktoren des Unternehmens zu sein. Der einj盲hrige Cliff-Vesting-Zeitplan entspricht typischen Aktienverg眉tungsstrukturen f眉r Vorstandsmitglieder. Die Einreichung wurde am 18. Juni 2025 vom Bevollm盲chtigten John R. Moore abgeschlossen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Morris Arlene
(Last) (First) (Middle)
C/O 1715 38TH STREET
(Street)
BOULDER CO 80301
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $14.68 06/16/2025 A 30,000 06/16/2026(1) 06/16/2035 Common Stock 30,000 $0.00 30,000 D
Explanation of Responses:
1. 100% of the Stock Options granted on June 16, 2025 will become vested on the earlier of (i) June 16, 2026 or (ii) the business day prior to the 2026 annual meeting of stockholders.
Remarks:
/s/ John R. Moore, Attorney-in-Fact for Morris Arlene 06/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What stock options were granted to Arlene Morris at EWTX on June 16, 2025?

Arlene Morris was granted 30,000 stock options with an exercise price of $14.68 per share. These options were granted on June 16, 2025, and have an expiration date of June 16, 2035.

When do Arlene Morris's EWTX stock options vest?

The stock options will vest 100% on the earlier of either (i) June 16, 2026, or (ii) the business day prior to EWTX's 2026 annual meeting of stockholders.

What is Arlene Morris's role at EWTX?

According to the Form 4 filing, Arlene Morris serves as a Director of Edgewise Therapeutics, Inc. (EWTX).

What is the exercise price of EWTX stock options granted in June 2025?

The stock options were granted with an exercise price of $14.68 per share.

How long do the EWTX stock options granted to Arlene Morris remain exercisable?

The stock options have a 10-year term, with an expiration date of June 16, 2035, starting from the grant date of June 16, 2025.
Stock EWTX logo
Edgewise Therapeutics, Inc.

NASDAQ:EWTX

EWTX Rankings

#3151 Ranked by Market Cap
N/A Ranked by Dividends

EWTX Latest News

Aug 7, 2025
Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Aug 6, 2025
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Jun 26, 2025
Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies
Jun 3, 2025
Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference
May 14, 2025
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025

EWTX Latest SEC Filings

Aug 7, 2025
[10-Q] Edgewise Therapeutics, Inc. Quarterly Earnings Report
Aug 7, 2025
[8-K] Edgewise Therapeutics, Inc. Reports Material Event
Jul 2, 2025
[Form 4] Edgewise Therapeutics, Inc. Insider Trading Activity
Jun 26, 2025
[8-K] Edgewise Therapeutics, Inc. Reports Material Event
Jun 18, 2025
[Form 4] Edgewise Therapeutics, Inc. Insider Trading Activity

EWTX Stock Data

1.42B
82.28M
0.42%
103.95%
10.53%
Biotechnology
Pharmaceutical Preparations
United States
BOULDER